Cleaner diets could save the US $50B
The free daily newsletter covering the top cardiovascular headlines
Related Articles
Medical malpractice lawsuits are rare in sports cardiology—but they can cost providers millions
When doctors are accused of mishandling the heart health of a young athlete, it occasionally ends up being settled in a courtroom.
At a crossroads: Surgical heart valve innovation slows as transcatheter treatments keep evolving
Has the success of TAVR and other interventional techniques had a negative impact on surgical valve innovation? Two surgeons shared their concerns in a new…
New TAVR valve from MiRus linked to positive early outcomes
The Siegel TAVR valve includes no nickel or cobalt. In fact, its frame was built using special alloys specifically developed by MiRus.
EHR-driven PCI risk assessments could make a world of difference
Researchers with Mayo Clinic have shown that EHR-driven risk assessments could go a long way toward improving care for PCI patients.
EHR-driven PCI risk assessments could make a world of difference
Researchers with Mayo Clinic have shown that EHR-driven risk assessments could go a long way toward improving care for PCI patients.
FDA expands approval of Boston Scientific’s Farapulse PFA system
The FDA’s 2024 approval of the Farapulse system covered patients with paroxysmal atrial fibrillation. Now, however, the technology is officially approved for patients with more…
TAVR patients with moderate or greater TR may face increased risks
When TAVR patients present with moderate or greater tricuspid regurgitation, it could impact the care team’s treatment strategy of choice.
American College of Cardiology now supports early use of medication to treat obesity
The group highlighted the proven effectiveness of these drugs, especially semaglutide and tirzepatide, while noting that eligibility, affordability and availability will still play key roles…
American College of Cardiology now supports early use of medication to treat obesity
The group highlighted the proven effectiveness of these drugs, especially semaglutide and tirzepatide, while noting that eligibility, affordability and availability will still play key roles…
Angiographic catheters recalled due to safety risk
The new Class I recall includes nearly 27,000 devices that could potentially experience a harmful defect during use.